EGFR and bone metastasis: Furthermore, patients with Stage IV LUAD and 19‐Del who received EGFR‐TKIs along with radiotherapy for bone metastasis achieved a longer OS duration than those with the 21‐L858R mutation (mOS: 34.7 vs. 25.1 months; 95% CI: 0.3915–0.8397; p = 0.0056) (Figure 2D).